english.prescrire.org > Prescrire International > N°77 - June 2005

n°77

June 2005

Issue Contents
Editorial

Free  Europe

p.82
Public investment needed

Marketing Authorisations

Tramadol oral solution (new drug)

p.83-85
Poorly evaluated and potentially dangerous in children

Chickenpox vaccines

p.85-91
A favourable risk-benefit balance in some situations

Etanercept (new indication)

p.92-93
For ankylosing spondylitis: another option

Bortezomib (new drug)

p.94-98
A last resort in myeloma: modest efficacy, major risks

Mycophenolate mofetil

p.99
Renal transplantation in children : efficacy similar to that in adults

Aprepitant

p.99
During highly emetic chemotherapy: less acute vomiting but too many drug interactions

Risperidone SR for injection

p.99
Long-term treatment of schizophrenia: few data, mainly negative

Adverse Effects

Topical retinoids during pregnancy (continued)

p.100-101
Cases of malformations were reported in women using retinoids topically

Free  Cox-2 inhibitors: still no decisive action

p.102
Industry interests over patients

Bupropion : a German review

p.103
Pancreatitis, among other problems

Galantamine : excess mortality

p.103
Data do not support its use

Fatal stroke with aripiprazole

p.103
Dose-dependent risk

Tramadol addiction

p.103
Risk of convulsion

Reviews

Management of insomnia

p.104-107
A place for traditional herbal remedies
Non drug measures come first for managing insomnia

Adjuvant hormone therapy for breast cancer

p.108-110
Alternatives to tamoxifen
Anastrozole can be an alternative to tamoxifen, notably in women at high risk of venous thromboembolism

Outlook

Free  Dangerous liaisons: patient groups and drug companies

p.111-112
Relying on funding and information from companies is not the best way to defend the needs and interests of patients

Free  WHO Commission on Intellectual Property, Innovation and Health

p.112-113
A petition calling on WHO to evaluate a proposal for a new global medical R&D treaty

Free  Drug packaging quality: neglected by regulatory agencies

p.114
Handling packaging and their accompanying devices is the only way to evaluate whether or not they are suitable for use by patients

Free  How to avoid future Vioxx°-type scandals

p.115-117
The market withdrawal of rofecoxib (Vioxx°)

2004 end-of-year statement by Association Mieux Prescrire (AMP)

p.118-119

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe